PT-141

Melanocortin receptor agonist - the only FDA-approved peptide for sexual arousal, marketed as Vyleesi.

Overview

PT-141 (bremelanotide) is a melanocortin-4 receptor agonist originally developed as a tanning agent before its pro-sexual effects were noticed. It's FDA-approved as Vyleesi for premenopausal hypoactive sexual desire disorder in women and is used widely off-label for both sexes as an on-demand libido and arousal peptide.

Unlike PDE5 inhibitors (Viagra, Cialis), PT-141 works centrally on arousal circuits in the brain rather than on peripheral vascular mechanics. This makes it useful when the issue is desire rather than erectile mechanics, and it can work in situations where Viagra doesn't.

It's a short-cycle, on-demand compound rather than a continuous protocol. Track BP (mild transient elevation common), nausea tolerance, and self-reported efficacy.

Mechanism of Action

PT-141 activates the melanocortin-4 receptor (MC4R) in the hypothalamus, stimulating central pro-sexual signaling independent of vascular effects. Downstream it increases dopamine release in the medial preoptic area, which is the classical arousal circuit.

Community Usage Patterns

1–2 mg SC injected 45–90 minutes before anticipated sexual activity. Effects last 2–8 hours. Common side effects: flushing, transient BP elevation, nausea (dose-dependent). Not for daily use - spacing ≥3 days apart is typical. Start at 0.5–1 mg to assess tolerance.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

PT-141 is a metabolite of melanotan II, not the same molecule

A persistent misconception is that PT-141 and melanotan II are interchangeable. Bremelanotide (PT-141) is a metabolite of melanotan II, differing by a single structural change: the C-terminal amide of melanotan II is replaced by a hydroxyl (carboxylic acid) group. That one substitution shifts the receptor-binding profile away from MC1R, the pigmentation receptor that drives tanning, and toward the central MC3R and MC4R pathways relevant to arousal.

This is part of why the two compounds are not clinically equivalent, and why residual pigmentation effects can still appear. Because bremelanotide retains melanocortin activity that includes MC1R, focal hyperpigmentation of the face, gums, and breasts has been documented with repeated dosing in the clinical trials, and in some participants it did not fully resolve after stopping. It is broadly the same on-target pharmacology, attenuated relative to the parent tanning peptide.

The melanocortin system explains nearly every side effect

Five melanocortin receptors sit downstream of a single peptide family:

- MC1R - skin and hair pigmentation (the tanning and hyperpigmentation signal) - MC2R - adrenal cortex (ACTH-driven cortisol; not meaningfully engaged by this compound) - MC3R and MC4R - hypothalamic energy balance, appetite, and sexual motivation - MC5R - exocrine gland function

Because bremelanotide is a non-selective agonist, its adverse-effect profile is not contamination, it is predictable receptor biology. The same MC4R activation associated with arousal also suppresses appetite and can trigger nausea. This is not incidental: setmelanotide (Imcivree), a selective MC4R agonist approved by the FDA in 2020 for rare genetic obesity, produces weight loss through the same receptor. Flushing, transient blood-pressure elevation, and nausea are the fingerprint of melanocortin agonism, which is why they tend to cluster together and are dose-dependent.

What the human evidence actually shows

The strongest human data comes from the RECONNECT program: two identical Phase 3 randomized, double-blind, placebo-controlled trials (Studies 301 and 302) in roughly 1,250 premenopausal women with acquired, generalized hypoactive sexual desire disorder, published by Kingsberg and colleagues in Obstetrics and Gynecology in 2019. Both trials met their two co-primary endpoints: a statistically significant improvement in the Female Sexual Function Index desire domain, and a reduction in desire-related distress on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (item 13).

The honest read is that statistical significance was clear but the effect sizes were modest. The desire-domain improvement over placebo was small in absolute terms, and responder analyses showed only a minority of women reaching a clinically meaningful threshold. Nausea was the dominant tolerability problem, reported by about 40 percent of participants versus roughly 1 percent on placebo, with flushing near 20 percent and headache around 11 percent. About 18 percent of women, roughly one in six, discontinued because of adverse reactions, compared with about 2 percent on placebo.

Human data in men is considerably thinner and older. Bremelanotide was originally studied as an intranasal formulation for erectile dysfunction, and that program was discontinued around 2008 largely over blood-pressure increases at higher doses. There is no modern large-scale randomized trial supporting the widespread off-label male use; that use rests on older erectile-dysfunction-era Phase 2 data and anecdote, which is worth stating plainly rather than overstating.

Biomarkers worth tracking, and why testosterone is on the list

Bremelanotide acts centrally and does not work through the endocrine axis, so it is not expected to meaningfully change testosterone, SHBG, or other sex hormones. The reason those markers are commonly tracked alongside it is differential, not causal: low desire has multiple drivers, and a hormonal workup helps a clinician clarify whether a melanocortin agonist is even the relevant lever.

- Blood pressure and heart rate - the one directly drug-related signal. In studies, systolic pressure rose transiently by several mmHg, peaking a few hours after dosing and resolving within roughly twelve hours, often alongside a small drop in heart rate. Baseline and periodic monitoring is standard clinical practice. - Total and free testosterone, SHBG - to identify a hormonal contributor to low libido that bremelanotide would not address. - Prolactin, estradiol, TSH - additional common components of a low-desire workup, since hyperprolactinemia and thyroid dysfunction are potentially reversible contributors.

Tracking these over time helps a person and their clinician see whether reported desire changes track with the compound or with an unrelated hormonal shift.

Cardiovascular cautions and the naltrexone interaction

The Vyleesi label reflects the melanocortin blood-pressure effect directly: use is limited to no more than one dose in 24 hours and no more than eight doses per month, and it is not recommended in uncontrolled hypertension or known cardiovascular disease.

A less obvious but well-documented interaction involves oral naltrexone. Bremelanotide slows gastric emptying, which can significantly reduce the absorption of orally administered naltrexone, roughly a 60 percent drop in peak concentration and a 40 percent drop in overall exposure in pharmacology studies. For someone taking naltrexone for alcohol or opioid use disorder, that reduced exposure can undermine the medication, a specific interaction flagged in the prescribing information and worth discussing with a licensed clinician.

Regulatory reality: Vyleesi is narrow, and research-chemical "PT-141" is not the same product

The FDA approval is specific: bremelanotide as Vyleesi, for acquired, generalized HSDD in premenopausal women, delivered by a fixed-dose autoinjector. It is not approved for men, for postmenopausal women, or for erectile dysfunction. Compounded or research-chemical "PT-141" sold outside that channel is a different regulatory category with no equivalent oversight of purity, dose accuracy, or sterility. The regulatory status of compounded and research-chemical peptides has continued to shift, so current status is best confirmed with a licensed clinician rather than assumed. Everything here is educational context for tracking a protocol, not medical advice or a recommendation to obtain or self-administer anything.

Biomarkers to Track

When running PT-141, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting PT-141, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for PT-141's class, and when to retest.

Reconstitution Calculator

Free calculator for PT-141 reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What PT-141 side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What PT-141 results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Pt 141 Bremelanotide Protocol →

Stacks That Include PT-141

PT-141 Head-to-Head Comparisons

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.